New approach using multiple microRNA ‘hitchhikers’ to weaken cancer cells in advance of standard therapy shows promise in preclinical models
In cancer therapeutics research, microRNAs–tiny strings of nucleotides that get churned out inside cells–have been a source of both excitement and disappointment. While preclinical studies have found that microRNAs play an important role in cancer and other diseases, two cancer clinical trials to date using microRNAs showed little response and significant toxicity. A team of investigators at Brigham and Women’s Hospital and Harvard Medical School has begun looking at these molecules in an entirely new way. Rather than modulating just one, they grouped together multiple microRNAs that naturally occur in the brain by encoding them in a small, artificial gene, and co-opted cancer cells’ molecular machinery to overproduce these groups of molecules to weaken the cells. Their approach has shown promising results in preclinical models, increasing survival in a murine model of glioblastoma by five-fold when combined with chemotherapy. The team’s results are published in Nature Communications.
“I like to think of it as hitchhiking. Cancer cells have a built-in system to produce and recognize microRNAs and we’re getting them to ‘pick up’ our sequence–which encodes multiple microRNAs–and start making more copies of them. The cellular machinery is running, and our sequence is along for the ride,” said corresponding author Pierpaolo Peruzzi, MD, PhD, an attending clinical neurosurgeon in the Department of Neurosurgery, as well as a principal investigator in the Harvey Cushing Neuro-Oncology Laboratories at the Brigham.
Peruzzi and colleagues, including lead author Vivek Bhaskaran, PhD, a postdoctoral fellow in the Department of Neurosurgery, set out to find groups of microRNAs responsible for regulating complex pathways. Using bioinformatic analysis, the team focused on a group of three microRNAs–miR-124, miR-128 and miR-137–which work as a team in properly developing neurons but are lost during the formation of brain cancer. The team found that several of these microRNAs’ targets included proteins involved in glioblastoma recurrence and resistance to conventional therapies.
The research team tested its findings using multiple cancer cell lines, including glioblastoma as well as non-glioblastoma cell lines. In addition, investigators tested the effectiveness of modulating all three microRNAs at once in a mouse model of intracranial tumors. The team reported a significant survival benefit. Without treatment, the mouse model survived 12 days post-tumor implantation, and chemotherapy extended this to a median of 18 days. But when chemotherapy and the multi-microRNA treatment were combined, survival was extended to a median of 48.5 days.
“These results are very encouraging and may provide a realistic treatment option,” said Bhaskaran.
Peruzzi notes that the multi-microRNA strategy weakens tumor cells but does not directly kill them. “While it seems a bit counterintuitive, this is actually an advantage, since by remaining alive, although severely impaired, cancer cells continue to produce microRNAs which eventually flood the entire tumor.” Indeed, the authors showed that these artificial microRNAs spread through the tumor through tiny vesicles and leave it more vulnerable to chemotherapy.
“We’re coaxing the tumor to produce its own poison, and then we hit it for good with chemotherapy or radiation,” said Peruzzi. “And we’re optimistic that in a relatively short time we can advance this approach to the clinic. A further refined and even more potent version of this concept is already in the pipeline.”
There are currently clinical trials underway at the Brigham leveraging viral vectors and gene therapy approaches for treating glioblastoma (both primary and recurrent). Peruzzi and colleagues are working to further refine their microRNA approach with the goal of using viral vectors to deliver these microRNAs to tumors in brain cancer patients.
Learn more: The hitchhiker’s guide to defeating glioblastoma
The Latest on: Glioblastoma
via Google News
The Latest on: Glioblastoma
- Dexamethasone May Be Detrimental to Immunotherapy in Glioblastoma Patientson November 25, 2020 at 12:00 pm
Historically, patients with glioblastoma have been empirically treated with dexamethasone, even without symptoms, with many clinicians prescribing steroids for prolonged periods of time, out of a ...
- Biopharma Targeting Glioblastoma Multiforme Commences Clinical Programon November 25, 2020 at 9:33 am
In a Nov. 23 research note, H.C. Wainwright & Co. analyst Robert Burns reported that Black Diamond Therapeutics Inc. (BDTX:NASDAQ) is beginning clinical development of its compound BDTX-1535 as a ...
- Immune checkpoint inhibitor efficacy against glioblastoma may decrease with dexamethasoneon November 25, 2020 at 1:07 am
Among patients with glioblastoma receiving an immune checkpoint inhibitor, those who received the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival, ...
- Dexamethasone use could reduce immune checkpoint inhibitor efficacy in glioblastoma patientson November 25, 2020 at 12:21 am
Among patients with glioblastoma receiving an immune checkpoint inhibitor, those who received the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival.
- Test for Deadly Brain Cancer Can Guide Crucial Decisionson November 24, 2020 at 10:15 am
One reason glioblastoma -- an aggressive brain cancer that affects more than 13,000 new people a year in the US -- is so deadly is that no tests are available to guide treatment or predict its outcome ...
- Black Diamond's EFGR-targeted glioblastoma drug candidate slows tumor growth in miceon November 23, 2020 at 5:26 am
Black Diamond Therapeutics was launched in 2018 with a goal of pursuing targeted cancer treatments from an entirely new angle. Instead of drugging mutated genes that drive cancer, Black Diamond set ...
- Black Diamond nominates development candidate for glioblastoma programon November 20, 2020 at 12:28 pm
Black Diamond Therapeutics (BDTX +2.6%) has nominated BDTX-1535 as the Company’s development candidate for the treatment of glioblastoma multiforme (GBM), an aggressive cancer in the brain or spinal ...
- Immunomic Therapeutics and CoImmune Therapeutics Enter into Partnership to Manufacture ITI-1020, a Novel Experimental Cell Therapy for Glioblastomaon November 20, 2020 at 1:24 am
Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, and CoImmune, Inc. (“CoImmune”), a privately ...
via Bing News